Risk of venous thromboembolism not significantly increased with VEGFR-TKIs

NEW YORK (Reuters Health) - Treating cancer patients with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) does not appear to increase their risk of venous thromboembolism, researchers from China report.
Source: Modern Medicine - Category: Journals (General) Source Type: news